Related Experiment Video
Updated: Aug 5, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Therapeutic modulation of low-density lipoprotein size
1Lipid Laboratory, Cape Heart Centre and MRC Cape Heart Group, University of Cape Town Health Sciences Faculty, Anzio Road, Observatory 7925, South Africa. dmarais@uctgsh1.uct.ac.za
Current Opinion in Lipidology
|November 22, 2000
Summary
Small, dense low-density lipoprotein (LDL) particles are linked to atherosclerosis and are an autosomal dominant trait. While lifestyle and drug interventions may alter LDL size, clinical benefits remain unproven.
Area of Science:
- Cardiovascular Science
- Metabolic Health
- Genetics
Background:
- Small, dense LDL particles are associated with atherosclerosis.
- This condition affects about 20% of adults, often alongside other risk factors.
- Recent studies highlight its genetic basis and links to metabolic issues.
Purpose of the Study:
- To review the current understanding of small, dense LDL particles.
- To explore their genetic determinants and associations with metabolic syndrome components.
- To assess the potential impact of interventions on LDL particle size and clinical outcomes.
Main Methods:
- Review of recent scientific literature and studies.
- Analysis of genetic and phenotypic data related to LDL particle size.
- Evaluation of evidence for lifestyle and pharmacological interventions.
Main Results:
- Small, dense LDL is confirmed as an autosomal dominant trait.
- Key influencing factors include hypertriglyceridemia, obesity, insulin resistance, and diabetes mellitus.
- Compositional and functional differences in small LDL are noted.
- Emerging evidence suggests interventions can modulate LDL size, but clinical benefit is not yet established.
Conclusions:
- Small, dense LDL particles represent a significant risk factor for atherosclerosis with a strong genetic component.
- Further research is needed to confirm the clinical utility of interventions targeting LDL particle size.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...